Mazor Robotics Ltd – (NASDAQ:MZOR) was downgraded by stock analysts at Barclays PLC from an “equal weight” rating to an “underweight” rating in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. They presently have a $34.00 price objective on the medical instruments supplier’s stock, down from their prior price objective of $55.00. Barclays PLC’s target price points to a potential downside of 36.81% from the stock’s current price.

Several other equities research analysts also recently commented on MZOR. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics Ltd – in a research note on Thursday, July 6th. Zacks Investment Research downgraded shares of Mazor Robotics Ltd – from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services set a $54.00 target price on shares of Mazor Robotics Ltd – and gave the company a “buy” rating in a research note on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $37.67.

Mazor Robotics Ltd – (MZOR) traded down 1.70% during trading on Thursday, reaching $53.81. 655,698 shares of the company’s stock traded hands. Mazor Robotics Ltd – has a 12 month low of $20.19 and a 12 month high of $59.59. The firm’s 50 day moving average is $49.50 and its 200 day moving average is $40.32. The company’s market cap is $1.30 billion.

Mazor Robotics Ltd – (NASDAQ:MZOR) last issued its earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.09. Mazor Robotics Ltd – had a negative net margin of 23.79% and a negative return on equity of 23.41%. The firm had revenue of $15.46 million during the quarter, compared to the consensus estimate of $15.38 million. During the same quarter in the prior year, the firm earned ($0.09) earnings per share. The business’s quarterly revenue was up 86.7% on a year-over-year basis. Analysts anticipate that Mazor Robotics Ltd – will post ($0.77) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/22/mazor-robotics-ltd-mzor-downgraded-to-underweight-at-barclays-plc.html.

Several hedge funds have recently modified their holdings of the company. Credit Suisse AG increased its position in shares of Mazor Robotics Ltd – by 66.5% during the first quarter. Credit Suisse AG now owns 330,000 shares of the medical instruments supplier’s stock worth $9,824,000 after acquiring an additional 131,804 shares in the last quarter. Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Mazor Robotics Ltd – during the second quarter worth $8,014,000. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Mazor Robotics Ltd – by 5.4% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 180,180 shares of the medical instruments supplier’s stock worth $6,231,000 after acquiring an additional 9,276 shares in the last quarter. Nepsis Capital Management Inc. bought a new stake in shares of Mazor Robotics Ltd – during the second quarter worth $5,873,000. Finally, Driehaus Capital Management LLC bought a new stake in shares of Mazor Robotics Ltd – during the first quarter worth $3,410,000. 25.92% of the stock is owned by institutional investors.

Mazor Robotics Ltd – Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics Ltd - (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.